MonJul 20th, 2020
Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma
DALLAS, TX – JULY 20, 2020 – Lantern Pharma (NASDAQ: [...]
MonJun 29th, 2020
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Datapoints, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Datapoints Curated Specifically for Oncology Drug Development and Drug Response Prediction
DALLAS, TX – JUNE 29, 2020 – Lantern Pharma (NASDAQ: [...]
WedJun 17th, 2020
Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting
Lantern Pharma to update leading cancer researchers and healthcare professionals [...]
MonJun 15th, 2020
Lantern Pharma Announces Closing of Initial Public Offering
DALLAS, June 15, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. [...]
WedJun 10th, 2020
Lantern Pharma Announces Pricing of Initial Public Offering
DALLAS, June 10, 2020 (GLOBE NEWSWIRE) -- Lantern Pharma Inc. [...]
TueDec 17th, 2019
Lantern Pharma Appoints David Margrave as Chief Financial Officer and Kishor Bhatia, Ph.D., as Chief Scientific Officer
Appointments bolster executive leadership by adding decades of collective and [...]
Let’s start a conversation about the future of cancer drug development.
We are a biotech pharma at the intersection of Artificial Intelligence, genomics, and oncology drug development.